Ocular Therapeutix

OCUL · NASDAQ

$6.65+$0.36 (+5.72%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $6.29

OCUL analyst rating

BuyConsensus of 10 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy10
Hold0
Underperform0
Sell0

12-month price target · 13 analysts

Average $27.26 (+310.0% upside)

Low: $18.18
Now: $6.65
High: $35.70

Upgrades and downgrades

The latest rating actions, newest first

OCUL analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Needham	Oct 19, 2026	Maintains	Buy	$18.00	53%
UBS	Oct 12, 2026	Initiates	Buy	$14.00	0%
Chardan Capital	Oct 2, 2026	Maintains	Buy	$23.00	45%
Needham	Sep 29, 2026	Maintains	Buy	$18.00	53%
Chardan Capital	Sep 16, 2026	Maintains	Buy	$23.00	53%
HC Wainwright & Co.	Sep 16, 2026	Maintains	Buy	$25.00	40%
Chardan Capital	Aug 4, 2026	Maintains	Buy	$23.00	53%
Chardan Capital	Jun 25, 2026	Maintains	Buy	$21.00 → $23.00	53%
HC Wainwright & Co.	Jun 18, 2026	Maintains	Buy	$21.00 → $25.00	40%
Baird	Jun 18, 2026	Maintains	Outperform	$24.00 → $30.00	38%

The case for and against

Updated Oct 14, 2026

Bull case

Ocular Therapeutix is fundamentally attractive because AXPAXLI offers a differentiated wet AMD profile with potential 9-12Mth durability, setting it apart from anti-VEGF competitors that still rely on more frequent dosing. The positive Pre-NDA meeting and unchanged 505(b)(2) path reduce regulatory risk, while the SOL-1 Week 52 efficacy and safety data, interim SOL-R safety analysis, and confirmatory evidence support a streamlined 4Q26 filing. With the only novel agent in wet AMD backed by a positive prespecified Phase 3 superiority trial versus an approved anti-VEGF, the thesis centers on commercial upside and label differentiation rather than execution risk.

Bear case

Ocular Therapeutix is viewed negatively because its investment case is concentrated in Axpaxli, a Phase 3 asset with no reported pivotal trial data and FDA approval still dependent on the adequacy of the overall NDA package. The company has one revenue-generating product, but the majority of its earning potential remains tied to uncommercialized assets, while it has incurred significant losses since inception and faces escalating development and commercialization expenses. Regulatory hurdles, intense competition from larger anti-VEGF players, reimbursement and physician-acceptance risks, and the need to secure additional funding or partnerships all heighten the odds of dilution, delays, and commercial underperformance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.